Summary of Presentations from the Britannia-sponsored Symposium, held at the Joint Congress of European Neurology (EFNS–ENS), Istanbul, Turkey, on 1st June 2014
Chairperson: Olivier Rascol1
Speakers: Fabrizio Stocchi,2 Stuart Isaacson,3 William Ondo4
1. Professor, Toulouse University Hospital Clinical Investigation Centre, Toulouse, France
2. Professor, Institute of Research and Medical Care, IRCCS San Raffaele, Rome, Italy
3. Associate Professor, Florida International University, Herbert Wertheim College School of Medicine, Miami; Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton; Research Director, Marcus Neuroscience Institute, Boca Raton Regional Hospital, Florida, USA
4. Professor, University of Texas Health Science Center, Houston, Texas, USA
Disclosure: This symposium was sponsored by Britannia Pharmaceuticals Limited.
Acknowledgements: Writing assistance was provided by Helen Lawn Associates PR Limited.
Support: The publication of this article was funded by Britannia Pharmaceuticals Limited. The views and opinions expressed are those of the authors and not necessarily of Britannia Pharmaceuticals Limited.
Citation: EMJ Neurol. 2014;1:27-35.
This educational symposium was held during the Joint Congress of European Neurology (EFNS–ENS), which took place from 31st May to 3rd June 2014 in Istanbul, Turkey, and was sponsored by Britannia Pharmaceuticals Limited. The symposium debated the problem of delayed ON and OFF periods in Parkinson’s disease that can occur even in patients optimised on oral medication. Emerging evidence for the rapid and effective resolution of such complications using apomorphine intermittent injection (penject) was reviewed with particular reference to the positive results of the recent AM IMPAKT trial in patients with morning akinaesia. The discussions were illustrated with examples of ‘real life’ patient case studies to help determine which patients might be best suited for treatment with apomorphine injection.